Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vertex's growth momentum remains strong, supported by ECC to S/4HANA migration and multi-year ERP upgrade cycle. Read my ...

Recent developments at Vertex include the initiation of Phase 3 trials for VX-522 for cystic fibrosis and VX-880 for type 1 diabetes, with promising initial data from the Povetacicept program for ...

Fintel reports that on November 4, 2024, Jefferies upgraded their outlook for Vertex (NasdaqGM:VERX) from Hold to Buy.

Analyst William Pickering of Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX ... implications for the ongoing DPN Phase 3 trial. However, the current market sentiment ...

Arkadios Wealth Advisors bought a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in ...

Gena Wang, an analyst from Barclays, maintained the Hold rating on Vertex Pharmaceuticals (VRTX ... The initiation of a Phase 3 trial for IgAN indicates progress, but the evaluation of ...

Vertex Pharmaceuticals continues to excel with strong Q3 results and promising clinical progress, but its valuation may ...

Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Vertex is rated Zacks Rank #3 (Hold).

The continued support comes after Vertex presented more detailed Phase 3 information on its non-opioid pain medication, Suzetrigine, at the Anesthesiology Meeting. The new data provided insights into ...

Recent developments at Vertex include the initiation of Phase 3 trials for VX-522 for cystic fibrosis and VX-880 for type 1 diabetes, with promising initial data from the Povetacicept program for IgA ...